|
|
Volumn 21, Issue 9, 2000, Pages 702-704
|
|
What have we learned from the recent large trials in acute coronary syndromes without ST-segment elevation?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
ANTITHROMBIN;
ANTITHROMBOCYTIC AGENT;
FIBRINOGEN RECEPTOR ANTAGONIST;
HEART ENZYME;
LOW MOLECULAR WEIGHT HEPARIN;
STREPTOKINASE;
TISSUE PLASMINOGEN ACTIVATOR;
TROPONIN;
ACUTE HEART INFARCTION;
CLINICAL FEATURE;
CLINICAL TRIAL;
CORONARY ARTERY DISEASE;
COST EFFECTIVENESS ANALYSIS;
DATA BASE;
DISEASE SEVERITY;
EDITORIAL;
FIBRINOLYSIS;
HEART MUSCLE REPERFUSION;
HEART MUSCLE REVASCULARIZATION;
HEART SURGERY;
HIGH RISK PATIENT;
HUMAN;
PATIENT CARE;
PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY;
PREDICTION;
PRIORITY JOURNAL;
PROGNOSIS;
Q WAVE;
ST SEGMENT ELEVATION;
STATISTICAL MODEL;
STROKE;
SYMPTOM;
THORAX PAIN;
TREATMENT OUTCOME;
UNSTABLE ANGINA PECTORIS;
CHEST PAIN;
CLINICAL TRIALS;
CORONARY DISEASE;
ELECTROCARDIOGRAPHY;
HUMANS;
MYOCARDIAL ISCHEMIA;
MYOCARDIAL REPERFUSION;
TREATMENT OUTCOME;
|
|
EID: 0034031675
PISSN: 0195668X
EISSN: None
Source Type: Journal
DOI: 10.1053/euhj.1999.2137 Document Type: Editorial |
|
Times cited : (3)
|
|
References (28)
|
